In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues - Correlation with clinical course

Leukemia

Volumn 12, Issue 8, 1998, Pages 1230-1235

  Bromidge, T J ^a   Turner, D L ^a   Howe, D J ^a   Johnson, S A ^a   Rule, S A J ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Chronic lymphocytic leukaemia; In vitro chemosensitivity; Purine analogue therapy

Indexed keywords

ANTILEUKEMIC AGENT; CLADRIBINE; CYCLOPHOSPHAMIDE; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; FLUDARABINE; PREDNISOLONE; PROTEIN BCL 2; PURINE DERIVATIVE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CROSS RESISTANCE; DISEASE COURSE; DRUG RESISTANCE; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

EID: 0031829418     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401095     Document Type: Article

References (28)

1. Johnson SA. Purine analogues in the management of lympholpro-liferative diseases. Clin Oncol 1996; 8: 289-296.
2. Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma 1994; 14: 3-9.
3. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes. J Clin Invest 1985; 75: 377-383.
4. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 1996; 2: 1731-1741.
5. Robertson LE, Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leuk Lymphoma 1993; 11: 71-74.
6. Raimondo FD, Palumbo GA, Romeo MA, Cacciola E, Milone G, Impera S, Giustolisi R, Cacciola E. In vitro sensitivity of B-CLL cells to fludarabine and interferons. Leuk Lymphoma 1995; 17: 449-453.
7. Li X, Gong J, Feldman E, Seiter K, Traganos F, Darzynkiewicz Z. Apoptotic cell death during treatment of leukemias. Leuk Lymphoma 1994; 13: 65-70.
8. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993; 53: 1945-1951.
9. Bosanquet AG, Bell PB. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood 1996; 86: 1962-1971.
10. Silber R, Degar B, Costin D, Newcombe EW, Mani M, Rosenberg CR, Morse L, Drygas JC, Canellakis ZN, Potmesil M. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994; 84: 3440-3446.
11. Juliusson G, Elmhorn-Rosenborg A, Liiemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 1992; 327: 1056-1061.
12. Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 1993; 328: 812.
13. Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 1993; 328: 812-813.
14. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreef M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxya-denosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. New Engl J Med 1994; 330: 319-322.
15. Morabito F, Stelitano C, Callea I, Filangeri M, Oliva B, Sculli G, Callea V, Nobile F, Brugiatelli M. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224-231.
16. Howe DJ, Bromidge TJ, Stack-Dunne M, Davies SV, Paxton A, Phillips MJ, Rule SJ, Johnson SA. Trisomy 12 is a rare event in cases of CLL with typical immunophenotype and morphology. Hematology 1997; 2: 373-378.
17. Oscier DG, Matutes E, Copplestone A, Pickering RM, Chapman R, Gillingham R, Catovsky D, Hamblin TJ. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol 1997; 98: 934-949.
18. Schena M, Larsson LG, Gottardi D, Gaidano GN, Carlsson M, Nilsson K, Caligaris-Cappio P. Growth and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992; 79: 2981-2989.
19. Hanada H, Delia D, Aiello A, Stadtmauer E, Reed JC. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820-1828.
20. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996; 10: 456-459.
21. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerises in vitro with a conserved homolog, bax, that accelerates programed cell death. Cell 1993; 74: 609-619.
22. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Dualt MT, Monconduit M, Belabbes S, Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multi-variate survival analysis. Cancer 1981; 48: 198-206.
23. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
24. Bromidge TJ, Howe DJ, Johnson SA, Phillips MJ. Adaptation of the TdT assay for semi-quantitative flow cytometric detection of DNA strand breaks. Cytometry 1995; 20: 257-260.
25. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989; 71: 343-350.
26. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkman M, Galle PR, Poustka A, Hunstein W, Lichter P. p 53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
27. Lowe SW, Ruley HE, Jacks T, Housman DE. p 53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
28. Thomas A, EI Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcombe EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p 53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055-1062.